首页> Molecular cancer therapeutics> HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.

HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Aïda,Sampera

第一单位： Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain.

作者： Aïda,Sampera ^[1] ; Francisco Javier,Sánchez-Martín ^[1] ; Oriol,Arpí ^[1] ; Laura,Visa ^[2] ; Mar,Iglesias ^[3] ; Sílvia,Menéndez ^[1] ; Élisabeth,Gaye ^[4] ; Alba,Dalmases ^[1] ; Sergi,Clavé ^[5] ; Mariona,Gelabert-Baldrich ^[1] ; Thomas Tuxen,Poulsen ^[6] ; Michael,Kragh ^[6] ; Beatriz,Bellosillo ^[5] ; Joan,Albanell ^[7] ; Ana,Rovira ^[8] ; Clara,Montagut ^[9]

作者单位： Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain. ^[1] Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain. ^[2] Department of Pathology, Hospital del Mar, Barcelona, Spain.;Universitat Autonoma de Barcelona, Spain. ^[3] Oncologie Médicale, Institut de Cáncerologie et Hématologie, Morvan, Brest, France. ^[4] Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain.;Department of Pathology, Hospital del Mar, Barcelona, Spain. ^[5] Symphogen A/S, Ballerup, Denmark. ^[6] Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain.;Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.;Universitat Pompeu Fabra, Barcelona, Spain. ^[7] Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain.;Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain. ^[8] Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain. cmontagut@hospitaldelmar.cat.;Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.;Universitat Pompeu Fabra, Barcelona, Spain. ^[9]